Anifrolumab
Saphnelo
- Dosage form
- Tablet
- Available strengths
- 300 mg/2 mL (intravenous vial), 120 mg/0.8 mL (subcutaneous autoinjector)
- Drug class
- Type I interferon receptor antagonist (monoclonal antibody)
- Common brand
- Saphnelo
Clinical overview. Anifrolumab is a monoclonal antibody biologic used, together with standard therapy, to treat adults with active systemic lupus erythematosus (SLE). It blocks the type I interferon receptor and can be given as a monthly intravenous infusion or a weekly self-injection. Key risks include increased susceptibility to infections, particularly shingles, and infusion or hypersensitivity reactions.
Indication
Common therapeutic uses
- Anifrolumab is used, in addition to standard therapy, to treat adults with active, autoantibody-positive systemic lupus erythematosus (SLE).
- Anifrolumab has not been studied in patients with severe active lupus nephritis or severe active central nervous system lupus, and its use is not recommended in these situations.
Pregnancy
Risk assessment and monitoring considerations
- Anifrolumab is not recommended during pregnancy or in women of childbearing potential who are not using contraception, since antibodies like anifrolumab can cross the placenta and animal studies showed increased pregnancy loss.
Breastfeeding
Infant exposure considerations
- The safety of anifrolumab during breastfeeding has not been established, it was detected in the milk of nursing monkeys, and a decision should be made whether to discontinue breastfeeding or discontinue the drug.
Geriatrics
Dosing and tolerability considerations
- Only a small number of patients 65 years and older, and none over 70, were included in clinical trials, so differences in safety or effectiveness in older adults compared with younger patients have not been determined.
Pediatrics
Use in children and adolescents
- Anifrolumab has not been studied in patients younger than 18 years old, and Health Canada has not authorized a pediatric indication.
Dosage & Administration
Practical dosing and administration
- The intravenous dose is 300 mg given as an infusion over 30 minutes, once every 4 weeks.
- The subcutaneous dose is 120 mg injected once weekly, preferably on the same day each week, rotating injection sites with each dose.
- When switching from intravenous to subcutaneous dosing, the first subcutaneous injection should be given about 2 weeks after the last intravenous dose.
- When switching from subcutaneous to intravenous dosing, the first infusion should be given about 3 to 4 weeks after the last subcutaneous dose.
- No dose adjustment is needed based on age, kidney function, or liver function, based on population pharmacokinetic modeling.
- If a planned intravenous infusion is missed, it should be given as soon as possible, keeping a minimum 14-day interval between doses.
- If a subcutaneous dose is missed, the patient should administer it as soon as remembered, then resume weekly dosing, keeping a minimum 3-day interval between injections.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- In clinical trials, doses of anifrolumab up to 1000 mg given intravenously did not cause any dose-limiting toxicity.
- There is no specific treatment for anifrolumab overdose; management is supportive with appropriate monitoring.
Common side effects
Frequently reported tolerability concerns
- Upper respiratory tract infection or pharyngitis may occur.
- Bronchitis may occur.
- Cough may occur.
- Infusion-related symptoms such as headache, nausea, or dizziness may occur.
- Cold sores (oral herpes) may occur.
- Joint pain (arthralgia) may occur.
- Pain in the arms or legs may occur.
- Vomiting may occur.
- Swelling in the legs (peripheral edema) may occur.
- Chest pain may occur.
- Depression may occur.
- Injection site reactions such as pain, redness, bruising, warmth, or itching may occur with the subcutaneous form.
- Diarrhea may occur, particularly with the subcutaneous form.
- Blurred vision may occur.
- Fatigue or general weakness (asthenia) may occur.
- Muscle pain (myalgia) may occur.
- Neck or back discomfort may occur.
- Elevated blood sugar or new-onset diabetes may occur.
- Elevated cholesterol or triglyceride levels may occur.
- Acne or eczema-like skin changes may occur.
- Tingling or numbness (hypoesthesia) may occur.
- Drowsiness (somnolence) may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Anifrolumab increases the risk of shingles (herpes zoster), including rare cases that spread across the body and require hospitalization.
- Serious, and sometimes fatal, infections have occurred.
- Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.
- Serious infusion-related reactions can occur during or shortly after the intravenous infusion.
- Malignancies (cancers) have been observed somewhat more often in patients treated with anifrolumab than with placebo, and the drug's full effect on cancer risk is not known.
- Seek urgent medical attention for signs of a severe allergic reaction, a widespread or painful shingles rash, or any sign of serious infection such as high fever or difficulty breathing.
Use with caution
Situations requiring closer assessment
- Use with caution in patients with a chronic infection, a history of recurrent infections, or known risk factors for infection.
- Do not start anifrolumab in a patient with a clinically significant active infection until it resolves or is adequately treated.
- Use with caution together with other biologic therapies, including B-cell-targeted therapies, since this combination has not been studied and is not recommended.
- Avoid live or attenuated vaccines while on anifrolumab, and complete recommended immunizations before starting treatment.
- Monitor patients for infection, and consider interrupting treatment if a significant infection develops or fails to respond to standard therapy.
- Use with caution in patients receiving intravenous infusions, ensuring staff are prepared to manage hypersensitivity or infusion reactions.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to anifrolumab or to any ingredient in the formulation or container.
Drug interactions
Clinically relevant combinations
- No formal drug-drug interaction studies have been performed with anifrolumab.
- Co-administration with oral corticosteroids did not significantly affect anifrolumab's pharmacokinetics.
- Co-administration with antimalarials did not significantly affect anifrolumab's pharmacokinetics.
- Co-administration with immunosuppressants such as azathioprine, methotrexate, mycophenolate mofetil, mycophenolic acid, or mizoribine did not significantly affect anifrolumab's pharmacokinetics.
- Co-administration with NSAIDs did not significantly affect anifrolumab's pharmacokinetics.
- Co-administration with ACE inhibitors did not significantly affect anifrolumab's pharmacokinetics.
- Co-administration with HMG-CoA reductase inhibitors (statins) did not significantly affect anifrolumab's pharmacokinetics.
- The effect of anifrolumab on the blood levels of these co-administered drugs has not been evaluated.
Food interactions
Meal-related administration
- No food interactions have been established for anifrolumab.
Time of administration
Practical scheduling
- The intravenous infusion is given once every 4 weeks by a healthcare professional; the subcutaneous injection is self-administered once weekly, preferably on the same day each week, without regard to meals.
Storage
Product handling
- Store the intravenous vial refrigerated between 2°C and 8°C, in the original package to protect from light, and do not freeze or shake it.
- Store the subcutaneous autoinjector refrigerated between 2°C and 8°C, protected from light; an unopened carton may be kept at room temperature for up to 7 days, and once removed from the fridge and warmed it must be used within 7 days or discarded.
- The diluted intravenous infusion solution may be stored at room temperature for up to 4 hours, or refrigerated for up to 24 hours, if not administered immediately.
Patient take-away
Key counselling points for a quick closing summary
- Anifrolumab is an add-on biologic treatment for adults with active systemic lupus erythematosus, given either as a monthly intravenous infusion or a weekly self-injection, that works by blocking interferon signaling; patients should watch for signs of infection, especially shingles, and seek prompt medical care for any severe allergic or infusion reaction.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.